

Anatara Annual General Meeting Results

MELBOURNE, 26 November 2020: Anatara Lifesciences (ASX: ANR) is pleased to announce the following results from the Annual General Meeting held on 26 November 2020.

At today's Annual General Meeting all Resolutions put to Shareholders were passed on a Poll.

Details of the Proxy and Poll Votes are attached.



STEPHEN DENARO

COMPANY SECRETARY

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anatara.com | Website anataralifesciences.com



ANATARA LIFESCIENCES LIMITED
2020 ANNUAL GENERAL MEETING
Thursday, 26 November 2020
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	15,795,382 88.06%	915,499 5.10%	1,225,494 6.84%	54,866	18,654,024 94.11%	1,168,263 5.89%	54,866	Carried
2 Re-election of Dr Jane Ryan	Ordinary	17,508,572 92.97%	100,000 0.53%	1,225,494 6.50%	237,944	20,619,978 99.52%	100,000 0.48%	237,944	Carried
3 Issue of Director Options to a Related Party – Ms Sue MacLeman	Ordinary	15,483,947 82.42%	2,078,815 11.06%	1,225,494 6.52%	283,754	18,595,353 89.94%	2,078,815 10.06%	283,754	Carried
4 Issue of Director Options to a Related Party – Dr Jane Ryan	Ordinary	15,529,757 82.46%	2,078,815 11.04%	1,225,494 6.50%	237,944	18,641,163 89.97%	2,078,815 10.03%	237,944	Carried
5 Issue of Director Options to a Related Party – Dr David Brookes	Ordinary	15,229,757 82.17%	2,078,815 11.22%	1,225,494 6.61%	537,944	18,341,163 89.82%	2,078,815 10.18%	537,944	Carried
6 Ratification of Tranche 1 Placement Shares	Ordinary	14,698,667 91.92%	66,666 0.42%	1,225,494 7.66%	54,866	16,765,164 99.60%	66,666 0.40%	54,866	Carried
7 Authority to issue Tranche 2 Placement Shares	Ordinary	17,724,984 93.21%	66,666 0.35%	1,225,494 6.44%	54,866	20,836,390 99.68%	66,666 0.32%	54,866	Carried
8 Authority to issue Broker Options	Ordinary	17,720,242 93.18%	71,408 0.38%	1,225,494 6.44%	54,866	20,831,648 99.66%	71,408 0.34%	54,866	Carried
9 Approval of 10% Placement Facility	Special	12,863,137 67.64%	4,928,513 25.92%	1,225,494 6.44%	54,866	15,871,263 75.93%	5,031,793 24.07%	54,866	Carried
10 Amendments to Constitution	Special	17,655,350 93.18%	66,666 0.35%	1,225,494 6.47%	124,500	20,766,756 99.68%	66,666 0.32%	124,500	Carried
11 Renewal of proportional takeover approval provisions	Special	17,755,350 93.22%	66,666 0.35%	1,225,494 6.43%	24,500	20,615,142 99.68%	66,666 0.32%	276,114	Carried
12 Renewal of Executive Option Plan	Ordinary	16,539,473 92.20%	171,408 0.96%	1,225,494 6.84%	207,290	19,399,265 97.87%	423,022 2.13%	207,290	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.